Antonius van Dijk - Jan 9, 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Scientific Officer
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact for Marcus Antonius van Dijk
Stock symbol
INKT
Transactions as of
Jan 9, 2023
Transactions value $
$63,482
Form type
4
Date filed
1/12/2023, 09:48 AM
Previous filing
Jan 25, 2022
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INKT Common Stock Award $120K +51.6K $2.32 51.6K Jan 9, 2023 Direct F1, F2
transaction INKT Common Stock Tax liability -$56.3K -24.3K -47% $2.32 27.4K Jan 9, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
F2 $2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.
F3 Represents payment of tax liability by withholding shares of common stock incident to the vesting of stock.